Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
ConditionHealthy Donors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCheckmab S.r.l.
About this trial
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
blood donors
age of 18 years or more
able to sign informed consent
Disqualifiers
age below 18 years
Positive for HIV, HCV, HBV
not suitable for blood donation
not able to understand or sign informed consent
Trial population
Healthy subjects
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 1 trial groupGroup A: Healthy Donors
Trial outcomes
Primary outcomes
1
Validation of molecular targets for immunotherapy
Time frame
04.2023-06.20262
Selection of therapeutic antibodies
Time frame
04.2023-06.2026Secondary outcomes
1
Set up of immunological assays to adress monoclonal antibodies mechanism of action
Time frame
04.2023-06.2026Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Checkmab S.r.l.
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator
Source ClinicalTrials.gov